{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:52Z","timestamp":1790742052531,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70764-x","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:27:11Z","timestamp":1774513631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ceramide disrupts TM9SF2-PGK1 axis to redirect PD-L1 trafficking and enhance antitumor immunity"],"prefix":"10.1038","volume":"17","author":[{"given":"Yi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxin","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yapeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshuo","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luning","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1830-338X","authenticated-orcid":false,"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-7937","authenticated-orcid":false,"given":"Ting","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"70764_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175, 313\u2013326 (2018).","journal-title":"Cell"},{"key":"70764_CR2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim, T. K., Vandsemb, E. N., Herbst, R. S. & Chen, L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529\u2013540 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70764_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","volume":"20","author":"SP Kubli","year":"2021","unstructured":"Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L. & Mak, T. W. Beyond immune checkpoint blockade: emerging immunological strategies. Nat. Rev. Drug Discov. 20, 899\u2013919 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70764_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura, P. et al. Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol. 10, 168 (2019).","journal-title":"Front. Immunol."},{"key":"70764_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"70764_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02027-x","volume":"10","author":"SH Choi","year":"2024","unstructured":"Choi, S. H. et al. DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy. Cell Death Discov. 10, 260 (2024).","journal-title":"Cell Death Discov."},{"key":"70764_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang, K. et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist. Updates 66, 100907 (2023).","journal-title":"Drug Resist. Updates"},{"key":"70764_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer cell 37, 443\u2013455 (2020).","journal-title":"Cancer cell"},{"key":"70764_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"70764_CR10","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"70764_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","volume":"33","author":"CW Li","year":"2018","unstructured":"Li, C. W. et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell 33, 187\u2013201.e110 (2018).","journal-title":"Cancer Cell"},{"key":"70764_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature23643","volume":"549","author":"ML Burr","year":"2017","unstructured":"Burr, M. L. et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101\u2013105 (2017).","journal-title":"Nature"},{"key":"70764_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25662-9","volume":"12","author":"Y Ren","year":"2021","unstructured":"Ren, Y. et al. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity. Nat. Commun. 12, 5405 (2021).","journal-title":"Nat. Commun."},{"key":"70764_CR14","doi-asserted-by":"publisher","unstructured":"Yu, X. et al. PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. J. Clin. Investig. 133, https:\/\/doi.org\/10.1172\/jci160456 (2023).","DOI":"10.1172\/jci160456"},{"key":"70764_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi, M., Niu, M., Xu, L., Luo, S. & Wu, K. Regulation of PD-L1 expression in the tumor microenvironment. J. Hematol. Oncol. 14, 10 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"70764_CR16","doi-asserted-by":"publisher","first-page":"e2206411","DOI":"10.1002\/advs.202206411","volume":"10","author":"Z Ye","year":"2023","unstructured":"Ye, Z. et al. Manipulation of PD-L1 Endosomal Trafficking Promotes Anticancer Immunity. Adv. Sci. 10, e2206411 (2023).","journal-title":"Adv. Sci."},{"key":"70764_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107084","volume":"201","author":"H Guo","year":"2024","unstructured":"Guo, H. et al. Insights into the role of derailed endocytic trafficking pathway in cancer: from the perspective of cancer hallmarks. Pharmacol. Res. 201, 107084 (2024).","journal-title":"Pharmacol. Res."},{"key":"70764_CR18","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2326-6066.CIR-22-0953","volume":"11","author":"EY Lemma","year":"2023","unstructured":"Lemma, E. Y., Letian, A., Altorki, N. K. & McGraw, T. E. Regulation of PD-L1 trafficking from synthesis to degradation. Cancer Immunol. Res. 11, 866\u2013874 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"70764_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat. Chem. Biol. 15, 42\u201350 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"70764_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48597-3","volume":"15","author":"X Xu","year":"2024","unstructured":"Xu, X. et al. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation. Nat. Commun. 15, 4237 (2024).","journal-title":"Nat. Commun."},{"key":"70764_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp4917","volume":"10","author":"T Dong","year":"2024","unstructured":"Dong, T. et al. Targeting VPS18 hampers retromer trafficking of PD-L1 and augments immunotherapy. Sci. Adv. 10, eadp4917 (2024).","journal-title":"Sci. Adv."},{"key":"70764_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature10742","volume":"481","author":"FX Contreras","year":"2012","unstructured":"Contreras, F. X. et al. Molecular recognition of a single sphingolipid species by a protein\u2019s transmembrane domain. Nature 481, 525\u2013529 (2012).","journal-title":"Nature"},{"key":"70764_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.molcel.2010.10.005","volume":"40","author":"DK Breslow","year":"2010","unstructured":"Breslow, D. K. & Weissman, J. S. Membranes in balance: mechanisms of sphingolipid homeostasis. Mol. cell 40, 267\u2013279 (2010).","journal-title":"Mol. cell"},{"key":"70764_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.chemphyslip.2018.08.003","volume":"216","author":"E Bieberich","year":"2018","unstructured":"Bieberich, E. Sphingolipids and lipid rafts: novel concepts and methods of analysis. Chem. Phys. lipids 216, 114\u2013131 (2018).","journal-title":"Chem. Phys. lipids"},{"key":"70764_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2017.107","volume":"19","author":"YA Hannun","year":"2018","unstructured":"Hannun, Y. A. & Obeid, L. M. Sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 19, 175\u2013191 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"70764_CR26","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s12276-023-01018-9","volume":"55","author":"M Lee","year":"2023","unstructured":"Lee, M., Lee, S. Y. & Bae, Y. S. Functional roles of sphingolipids in immunity and their implication in disease. Exp. Mol. Med. 55, 1110\u20131130 (2023).","journal-title":"Exp. Mol. Med."},{"key":"70764_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0378-1119(97)00263-1","volume":"197","author":"J Chluba-de Tapia","year":"1997","unstructured":"Chluba-de Tapia, J., de Tapia, M., J\u00e4ggin, V. & Eberle, A. N. Cloning of a human multispanning membrane protein cDNA: evidence for a new protein family. Gene 197, 195\u2013204 (1997).","journal-title":"Gene"},{"key":"70764_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0378-1119(98)00349-7","volume":"216","author":"F Schimm\u00f6ller","year":"1998","unstructured":"Schimm\u00f6ller, F., D\u00edaz, E., M\u00fchlbauer, B. & Pfeffer, S. R. Characterization of a 76 kDa endosomal, multispanning membrane protein that is highly conserved throughout evolution. Gene 216, 311\u2013318 (1998).","journal-title":"Gene"},{"key":"70764_CR29","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/embor.2009.236","volume":"10","author":"F Lozupone","year":"2009","unstructured":"Lozupone, F. et al. The human homologue of Dictyostelium discoideum phg1A is expressed by human metastatic melanoma cells. EMBO Rep. 10, 1348\u20131354 (2009).","journal-title":"EMBO Rep."},{"key":"70764_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccell.2023.12.010","volume":"42","author":"ME Hoekstra","year":"2024","unstructured":"Hoekstra, M. E. et al. Distinct spatiotemporal dynamics of CD8(+) T cell-derived cytokines in the tumor microenvironment. Cancer Cell 42, 157\u2013-167.e159 (2024).","journal-title":"Cancer Cell"},{"key":"70764_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","volume":"254","author":"E Aktas","year":"2009","unstructured":"Aktas, E., Kucuksezer, U. C., Bilgic, S., Erten, G. & Deniz, G. Relationship between CD107a expression and cytotoxic activity. Cell. Immunol. 254, 149\u2013154 (2009).","journal-title":"Cell. Immunol."},{"key":"70764_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.31083\/j.fbl2903092","volume":"29","author":"A Qiu","year":"2024","unstructured":"Qiu, A. et al. Phosphoglycerate Kinase 1: An effective therapeutic target in cancer. Front. Biosci. 29, 92 (2024).","journal-title":"Front. Biosci."},{"key":"70764_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41419-024-06544-6","volume":"15","author":"H Liu","year":"2024","unstructured":"Liu, H. et al. PRMT1-mediated PGK1 arginine methylation promotes colorectal cancer glycolysis and tumorigenesis. Cell Death Dis. 15, 170 (2024).","journal-title":"Cell Death Dis."},{"key":"70764_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45443-4","volume":"15","author":"SL Chu","year":"2024","unstructured":"Chu, S. L. et al. Phosphoglycerate kinase 1 acts as a cargo adaptor to promote EGFR transport to the lysosome. Nat. Commun. 15, 1021 (2024).","journal-title":"Nat. Commun."},{"key":"70764_CR35","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1016\/j.apsb.2022.05.012","volume":"12","author":"L Liao","year":"2022","unstructured":"Liao, L. et al. A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1\u03b2 and IL-6. Acta Pharm. Sin. B 12, 4180\u20134192 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"70764_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12221-6","volume":"10","author":"A Singla","year":"2019","unstructured":"Singla, A. et al. Endosomal PI(3)P regulation by the COMMD\/CCDC22\/CCDC93 (CCC) complex controls membrane protein recycling. Nat. Commun. 10, 4271 (2019).","journal-title":"Nat. Commun."},{"key":"70764_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.isci.2018.12.039","volume":"11","author":"T Yamaji","year":"2019","unstructured":"Yamaji, T. et al. A CRISPR screen identifies LAPTM4A and TM9SF proteins as glycolipid-regulating factors. iScience 11, 409\u2013424 (2019).","journal-title":"iScience"},{"key":"70764_CR38","first-page":"2280","volume":"9","author":"Y He","year":"2019","unstructured":"He, Y. et al. PGK1-mediated cancer progression and drug resistance. Am. J. Cancer Res. 9, 2280\u20132302 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"70764_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2023.151337","volume":"102","author":"J Alizadeh","year":"2023","unstructured":"Alizadeh, J. et al. Ceramides and ceramide synthases in cancer: Focus on apoptosis and autophagy. Eur. J. Cell Biol. 102, 151337 (2023).","journal-title":"Eur. J. Cell Biol."},{"key":"70764_CR40","doi-asserted-by":"publisher","unstructured":"Tanaka, A. et al. Genome-wide screening uncovers the significance of N-Sulfation of heparan sulfate as a host cell factor for chikungunya virus infection. J. Virol. 91, https:\/\/doi.org\/10.1128\/jvi.00432-17 (2017).","DOI":"10.1128\/jvi.00432-17"},{"key":"70764_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41419-019-1896-3","volume":"10","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. LINC01232 exerts oncogenic activities in pancreatic adenocarcinoma via regulation of TM9SF2. Cell Death Dis. 10, 698 (2019).","journal-title":"Cell Death Dis."},{"key":"70764_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33527-3","volume":"8","author":"CR Clark","year":"2018","unstructured":"Clark, C. R. et al. Transposon mutagenesis screen in mice identifies TM9SF2 as a novel colorectal cancer oncogene. Sci. Rep. 8, 15327 (2018).","journal-title":"Sci. Rep."},{"key":"70764_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117863","volume":"256","author":"Q Fu","year":"2020","unstructured":"Fu, Q. & Yu, Z. Phosphoglycerate kinase 1 (PGK1) in cancer: a promising target for diagnosis and therapy. Life Sci. 256, 117863 (2020).","journal-title":"Life Sci."},{"key":"70764_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13601-8","volume":"11","author":"H Nie","year":"2020","unstructured":"Nie, H. et al. O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth. Nat. Commun. 11, 36 (2020).","journal-title":"Nat. Commun."},{"key":"70764_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2024.159463","volume":"1869","author":"L Foug\u00e8re","year":"2024","unstructured":"Foug\u00e8re, L., Mongrand, S. & Boutt\u00e9, Y. The function of sphingolipids in membrane trafficking and cell signaling in plants, in comparison with yeast and animal cells. Biochim. et. Biophys. Acta Mol. Cell Biol. Lipids 1869, 159463 (2024).","journal-title":"Biochim. et. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"70764_CR46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.bbalip.2007.01.009","volume":"1771","author":"K Hanada","year":"2007","unstructured":"Hanada, K., Kumagai, K., Tomishige, N. & Kawano, M. CERT and intracellular trafficking of ceramide. Biochim. et. Biophys. Acta 1771, 644\u2013653 (2007).","journal-title":"Biochim. et. Biophys. Acta"},{"key":"70764_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc3398","volume":"13","author":"SA Morad","year":"2013","unstructured":"Morad, S. A. & Cabot, M. C. Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer 13, 51\u201365 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"70764_CR48","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrc1411","volume":"4","author":"B Ogretmen","year":"2004","unstructured":"Ogretmen, B. & Hannun, Y. A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 4, 604\u2013616 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"70764_CR49","doi-asserted-by":"publisher","unstructured":"Finicle, B. T. et al. Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6. J. Cell Sci. 131, https:\/\/doi.org\/10.1242\/jcs.213314 (2018).","DOI":"10.1242\/jcs.213314"},{"key":"70764_CR50","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nature02188","volume":"426","author":"K Hanada","year":"2003","unstructured":"Hanada, K. et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature 426, 803\u2013809 (2003).","journal-title":"Nature"},{"key":"70764_CR51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41574-020-0320-5","volume":"16","author":"SM Turpin-Nolan","year":"2020","unstructured":"Turpin-Nolan, S. M. & Br\u00fcning, J. C. The role of ceramides in metabolic disorders: when size and localization matters. Nat. Rev. Endocrinol. 16, 224\u2013233 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"70764_CR52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-4939-1862-1_10","volume":"1239","author":"L Cong","year":"2015","unstructured":"Cong, L. & Zhang, F. Genome engineering using CRISPR-Cas9 system. Methods Mol. Biol. 1239, 197\u2013217 (2015).","journal-title":"Methods Mol. Biol."},{"key":"70764_CR53","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41586-024-07098-5","volume":"627","author":"AG York","year":"2024","unstructured":"York, A. G. et al. IL-10 constrains sphingolipid metabolism to limit inflammation. Nature 627, 628\u2013635 (2024).","journal-title":"Nature"},{"key":"70764_CR54","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 186, 3903\u20133920.e3921 (2023).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70764-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70764-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70764-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:03:19Z","timestamp":1779354199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70764-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70764"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70764-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4525"}}